U.S. Capital Wealth Advisors LLC Acquires 1,587 Shares of CME Group Inc. (NASDAQ:CME)

U.S. Capital Wealth Advisors LLC lifted its stake in CME Group Inc. (NASDAQ:CME - Free Report) by 4.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,807 shares of the financial services provider's stock after acquiring an additional 1,587 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in CME Group were worth $10,295,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Wayfinding Financial LLC bought a new stake in shares of CME Group during the first quarter valued at approximately $25,000. Golden State Wealth Management LLC raised its stake in shares of CME Group by 612.5% in the 1st quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock valued at $30,000 after buying an additional 98 shares in the last quarter. Alpine Bank Wealth Management bought a new position in shares of CME Group during the 1st quarter worth about $32,000. New Age Alpha Advisors LLC lifted its holdings in shares of CME Group by 50.0% during the 4th quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock worth $30,000 after acquiring an additional 43 shares during the period. Finally, Knuff & Co LLC bought a new position in shares of CME Group during the 4th quarter worth about $33,000. Institutional investors own 87.75% of the company's stock.

CME Group Price Performance

Shares of NASDAQ CME traded down $6.92 during trading on Tuesday, reaching $275.63. The company had a trading volume of 3,437,292 shares, compared to its average volume of 2,193,826. CME Group Inc. has a 52 week low of $193.17 and a 52 week high of $290.79. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02. The business's 50 day moving average price is $276.69 and its 200-day moving average price is $258.49. The stock has a market cap of $99.33 billion, a PE ratio of 26.76, a PEG ratio of 3.83 and a beta of 0.44.

CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.61 by $0.19. The firm had revenue of $1.64 billion for the quarter, compared to the consensus estimate of $1.56 billion. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The business's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.50 EPS. Analysts expect that CME Group Inc. will post 10.49 earnings per share for the current year.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th were given a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a dividend yield of 1.81%. The ex-dividend date of this dividend was Monday, June 9th. CME Group's payout ratio is 50.30%.

Insider Activity at CME Group

In other news, Director Daniel G. Kaye sold 500 shares of CME Group stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $282.42, for a total transaction of $141,210.00. Following the transaction, the director owned 3,668 shares in the company, valued at $1,035,916.56. The trade was a 12.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Phyllis M. Lockett sold 1,060 shares of the business's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $277.88, for a total value of $294,552.80. Following the completion of the transaction, the director owned 3,108 shares of the company's stock, valued at $863,651.04. This represents a 25.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,400 shares of company stock worth $3,680,610. 0.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CME has been the topic of a number of recent research reports. Morgan Stanley lifted their price objective on CME Group from $301.00 to $304.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Keefe, Bruyette & Woods raised their target price on CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research report on Thursday, April 24th. Wall Street Zen upgraded CME Group from a "sell" rating to a "hold" rating in a research report on Saturday. Citigroup increased their price objective on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research note on Thursday, July 3rd. Finally, Oppenheimer boosted their target price on shares of CME Group from $282.00 to $300.00 and gave the company an "outperform" rating in a research note on Wednesday, June 4th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $259.87.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.